Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Hodgkin lymphoma, drawn from the whole corpus: 105 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
10 medicines on record are linked to one of the types below rather than to Hodgkin lymphoma itself. Grouped by the type that holds them; each list opens that type's own page.
Late toxicity in survivors.
Background: Quality of life. Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Older patients.
Late effects dominate: cardiac disease, breast and lung cancer after mediastinal radiotherapy, infertility; survivors need lifelong surveillance that most health systems do not organise.
Background: Quality of life. Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Older patients (>60) have roughly half the cure rate and double the toxicity; the best regimen for them is unsettled.
Background: Quality of life. Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
The ~10-15% with primary refractory or early-relapsing disease still need transplant; those failing PD-1 blockade have few options beyond allogeneic transplant.
Nothing recorded yet.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Interim PET has limited positive predictive value; ctDNA-guided designs are unproven.
Access: brentuximab and nivolumab are costly and unavailable in many countries where EBV-positive Hodgkin lymphoma is common in children.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Nodular lymphocyte-predominant disease is now a separate entity with little trial evidence of its own.
Radiotherapy omission trades a few percent of PFS for lower late toxicity; the right trade-off differs by age and sex.
Background: Quality of life. Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Three countries now have three different standards for the same advanced-stage disease: nivolumab with AVD in the United States after SWOG S1826, PET-guided BrECADD in Germany after HD21, and PET-adapted ABVD or brentuximab-AVD in much of the United Kingdom. They have never been compared with each other, and none has overall survival data at the timescale on which this disease is measured.
The consequences of PD-1 blockade given to a 20-year-old who will live another sixty years are unknown, and the trials that made it a first-line standard have a few years of follow-up in a disease whose main late harms appear after twenty.
Omitting radiotherapy in PET-negative early-stage disease costs several percentage points of disease control in both HD16 and RAPID and costs nothing in survival, and there is no way to tell an individual patient whether they are one of the people it would have saved a relapse.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Older patients tolerate every intensive Hodgkin regimen poorly and are excluded from most trials, so the commonest treatment failure in this disease happens in the group with the least evidence.
Every attempt to omit radiotherapy from early-stage Hodgkin lymphoma on the strength of a negative interim scan has cost tumour control: 7.3 percentage points in HD16 and a failure to demonstrate non-inferiority in either risk group of EORTC H10.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
The late-effect figures that justify de-escalation come from patients treated up to 2000 with mantle fields. Nobody knows the forty-year risks of involved-site radiotherapy, brentuximab vedotin, checkpoint inhibitors or CAR-T, and the field is making decisions on a harm estimate drawn from a treatment that is no longer given.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 62 changes by month →When this page itself was last checked or edited.
First-line advanced classical Hodgkin lymphoma with AVD, age ≥12 (SWOG S1826)
Untreated advanced classical Hodgkin lymphoma with AVD, age ≥12
Nivolumab-AVD × 6 (S1826; approved March 2026, no routine radiotherapy) or BV-AVD × 6 with G-CSF (ECHELON-1); in Europe PET-guided BrECADD × 4-6 (HD21) or eBEACOPP; PET-adapted ABVD/AVD (RATHL) where novel agents unavailable. (NCCN Category 1 (nivolumab-AVD preferred; BV-AVD), ESMO-MCBS A (ECHELON-1))
ABVD × 4 + ISRT 30 Gy, or escalated BEACOPP × 2 + ABVD × 2 + RT (HD14/HD17 PET-guided); nivolumab- or BV-containing regimens in trials. (NCCN Category 2A)
Salvage (ICE, DHAP, GVD, BV-nivolumab or pembrolizumab-GVD) → PET-negative → high-dose therapy and autologous transplant; brentuximab consolidation for high-risk (AETHERA); PD-1 maintenance in trials. (NCCN Category 1 (ASCT after chemosensitive salvage; BV consolidation for high risk))